NCT03914625 2026-03-18
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 3 Active not recruiting
Clinical Trials
12 trialsNCT06124157 2026-03-13
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT06717347 2026-03-13
MK-2140-010
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06925737 2026-03-13
MK-2400-001
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06091254 2026-03-11
OLYMPIA-1
Regeneron Pharmaceuticals
Phase 3 Recruiting
NCT03007147 2026-02-23
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Children's Oncology Group
Phase 3 Active not recruiting
NCT05888493 2026-02-20
LEDA
Novartis
Phase 3 Active not recruiting
NCT00400946 2026-02-13
05-001: Treatment of Acute Lymphoblastic Leukemia in Children
Dana-Farber Cancer Institute
Phase 3 Completed
NCT06091865 2026-02-05
OLYMPIA-3
Regeneron Pharmaceuticals
Phase 3 Active not recruiting
NCT06764485 2026-01-28
rechARge
Celgene
Phase 3 Recruiting
NCT07365995 2026-01-26
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
BioNTech SE
Phase 3 Not yet recruiting
NCT06220032 2026-01-05
HO170DLBCL
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3 Recruiting